162 related articles for article (PubMed ID: 9355683)
1. Cyclosporin in pediatric rheumatology; a seven years experience.
Gattinara M; Lomater C; Gerloni V; Mazzotti J; Fantini F
Acta Univ Carol Med (Praha); 1994; 40(1-4):105-8. PubMed ID: 9355683
[No Abstract] [Full Text] [Related]
2. Pediatric rheumatology for the adult rheumatologist.
Wagner-Weiner L
J Clin Rheumatol; 2008 Apr; 14(2):109-19. PubMed ID: 18391684
[TBL] [Abstract][Full Text] [Related]
3. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center].
de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C
Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652
[TBL] [Abstract][Full Text] [Related]
4. [Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group Pediatric Rheumatology Austria].
Niehues T; Horneff G; Michels H; Sailer Höck M; Schuchmann L
Z Rheumatol; 2004 Apr; 63(2):147-58. PubMed ID: 15112095
[TBL] [Abstract][Full Text] [Related]
5. [Rheumatoid arthritis in children: modifying effect of cyclosporin A].
Alekseeva EI; Shakhbazian IE; Isaeva KB; Khudoleeva EIu; Chistiakova EG
Klin Med (Mosk); 1998; 76(1):46-9. PubMed ID: 9532917
[No Abstract] [Full Text] [Related]
6. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey.
Stringer E; Bohnsack J; Bowyer SL; Griffin TA; Huber AM; Lang B; Lindsley CB; Ota S; Pilkington C; Reed AM; Scuccimarri R; Feldman BM
J Rheumatol; 2010 Sep; 37(9):1953-61. PubMed ID: 20595275
[TBL] [Abstract][Full Text] [Related]
7. Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.
Qushmaq KA; Chalmers A; Esdaile JM
J Rheumatol; 2000 Dec; 27(12):2855-9. PubMed ID: 11128676
[TBL] [Abstract][Full Text] [Related]
8. [Sandimmun-Neoral--a new quality of life for patients with severe systemic juvenile rheumatoid arthritis].
Alekseeva EI; Shakhbazian IE
Ter Arkh; 1999; 71(5):26-9. PubMed ID: 10399226
[TBL] [Abstract][Full Text] [Related]
9. [Advances in pediatric and adolescent rheumatology: national and international cooperation].
Huppertz HI
Z Rheumatol; 2010 Aug; 69(6):486-7. PubMed ID: 20632180
[No Abstract] [Full Text] [Related]
10. Anakinra for systemic juvenile arthritis: the Rocky Mountain experience.
Zeft A; Hollister R; LaFleur B; Sampath P; Soep J; McNally B; Kunkel G; Schlesinger M; Bohnsack J
J Clin Rheumatol; 2009 Jun; 15(4):161-4. PubMed ID: 19363453
[TBL] [Abstract][Full Text] [Related]
11. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus-associated B cell lymphoproliferative disease in a child with neonatal-onset multisystem inflammatory disease.
Modica R; Emery H; Lam W; Hermiston M; Grenert J; Wirt M; von Scheven E
Arthritis Rheum; 2006 Oct; 55(5):823-5. PubMed ID: 17013844
[No Abstract] [Full Text] [Related]
13. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.
Lovell DJ; Reiff A; Jones OY; Schneider R; Nocton J; Stein LD; Gedalia A; Ilowite NT; Wallace CA; Whitmore JB; White B; Giannini EH;
Arthritis Rheum; 2006 Jun; 54(6):1987-94. PubMed ID: 16732547
[TBL] [Abstract][Full Text] [Related]
15. Neutrophilic panniculitis in infancy: a cutaneous manifestation of juvenile rheumatoid arthritis.
Dyer JA; Guitart J; Klein-Gitelman M; Mancini AJ
J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S65-8. PubMed ID: 17938028
[TBL] [Abstract][Full Text] [Related]
16. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
17. Clinical trials in pediatric rheumatology: comment on the editorial by Lehman.
DeWitt EM; Ardoin SP; Rabinovich CE; Schanberg LE
Arthritis Rheum; 2008 Apr; 58(4):1202-3; author reply 1203. PubMed ID: 18383362
[No Abstract] [Full Text] [Related]
18. The Pediatric Rheumatology Collaborative Study Group--the first nine years.
Brewer EJ
J Rheumatol; 1982; 9(1):1-2. PubMed ID: 7045357
[No Abstract] [Full Text] [Related]
19. Future trends in pediatric rheumatology.
Fantini F
J Rheumatol Suppl; 1993 Apr; 37():49-53. PubMed ID: 8501754
[No Abstract] [Full Text] [Related]
20. MonitorNet: the Italian multi-centre observational study aimed at estimating the risk/benefit profile of biologic agents in real-world rheumatology practice.
Sfriso P; Salaffi F; Montecucco CM; Bombardieri S; Todesco S
Reumatismo; 2009; 61(2):132-9. PubMed ID: 19633800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
